Vanda Pharma Q3 Sales $38.81M Miss $44.50M Estimate
Portfolio Pulse from saritha@benzinga.com
Vanda Pharma reported Q3 sales of $38.81 million, missing the analyst consensus estimate of $44.50 million by 12.78 percent. This represents a 40.58 percent decrease compared to the same period last year.
November 08, 2023 | 9:42 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vanda Pharma's Q3 sales missed the analyst consensus estimate by 12.78%, a significant decrease from the same period last year.
Vanda Pharma's Q3 sales fell short of analyst estimates, which is likely to negatively impact investor sentiment and potentially the stock price in the short term. The significant YoY decrease further underscores the company's underperformance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100